The objective of this Pilot Study is to demonstrate the efficacy of the Hemocept device in detecting changes in arterial blood volume and cardiac efficiency.
Eligibility
Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria:
* Subjects or representatives must have voluntarily signed the informed consent form before any study related procedures.
* Subjects can be any gender but must be between (and including) the ages of 18 and 80.
* Subject ls being treated by the participating healthcare facility .
., Subject requires a trans-aortic valve replacement.
* Subject is able and willing to provide informed consent and HIPM authorization.
* Subject is able and willing to meet all study requirements.
Exclusion Criteria:
* Subject is pregnant, breast-feeding, or intends to become pregnant during the course of the study.
* Subject has a personal medical history that includes:
* Long O-T syndrome
* Cardiac channelopathies
* Seizures
Primary outcome measure(s)
Correlation of HemoCept device measurements with aortic valve pressure gradient changes. — Perioperative; immediately before procedure, and up to 24 hours after the procedure The primary endpoint is the ability of the HemoCept device to properly detect changes consistent with aortic valve pressure gradient values, measured by echocardiogram pre and post TAVR procedure.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.